

# Asparaginase

NOT RECOMMENDED AS AN  
ESSENTIAL MEDICINE

Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.1. Cytotoxic medicines

		EMLc	Codes ATC: L01XX02
Indication	Unspecified malignant neoplasms of ill-defined or unspecified sites	Code ICD11: 2D9Z	
Type de médicament	Biological agent		
Type de liste	Liste complémentaire (EML) (EMLc)		
Formulations	Powder for injection: 10 000 IU in vial.		
Historique des statuts LME	Ajouté pour la première fois en 1993 (TRS 850) Modifié en 2007 (TRS 950) Retiré en 2015 (TRS 994)		
Sexe	Tous		
Âge	Aussi recommandé pour les enfants		
Équivalence thérapeutique	La recommandation concerne ce médicament spécifique		
Renseignements sur le brevet	Patents have expired in most jurisdictions Lire la suite <a href="#">sur les brevets.</a> ↗		
Balises	<a href="#">Cancer</a> <a href="#">Biological</a>		
Wikipédia	<a href="#">Asparaginase</a> ↗		
DrugBank	<a href="#">Asparaginase</a> ↗		

## Résumé des preuves et recommandation du comité d'experts

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of asparaginase was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for asparaginase for more information.

